ReviewPharmacology & therapeutics2017
Novel pharmacotherapies for cardiac amyloidosis.
Review in Pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.The New England journal of medicine · 2018Trial
- Brain Amyloid Deposition Is Negatively Associated with Cardiac Amyloid Retention in Apo E4 Carriers: A Pilot Study.Molecular imaging and biology · 2026Article
- Analysis and insights of cardiac amyloidosis: novel perception of rare diseases in cardiology.American journal of translational research · 2024Article
- Cardiac amyloidosis: A survey of current awareness, diagnostic modalities, treatment practices, and clinical challenges among cardiologists in selected Middle Eastern countries.Clinical cardiology · 2023Article
- The utility of positron emission tomography in cardiac amyloidosis.Heart failure reviews · 2022Review
- Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Positron emission tomography for cardiac amyloidosis: Timing matters!Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Article
- Using Big Data to Understand Rare Diseases.International journal of heart failure · 2021Article
- Recent advances in the diagnosis and management of amyloid cardiomyopathy.Faculty reviews · 2021Review
- Evaluating Prognosis in AL Amyloidosis: Can LV Strain Play a Role?JACC. CardioOncology · 2020Article
- Amyloid and the Heart.Current cardiology reports · 2019Review
- Detection of cardiac amyloidosis withEuropean journal of nuclear medicine and molecular imaging · 2019Article
- 3D myocardial deformation analysis from cine MRI as a marker of amyloid protein burden in cardiac amyloidosis: validation versus T1 mapping.The international journal of cardiovascular imaging · 2018Article
- Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis.JAMA cardiology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Amyloidosis refers to a range of protein misfolding disorders that can cause organ dysfunction through progressive fibril deposition. Cardiac involvement often leads to significant morbidity and mortality and increasingly has been recognized as an important cause of heart failure. The two main forms of cardiac amyloidosis, light chain (AL) and transthyretin (ATTR) amyloidosis, have distinct mechanisms of pathogenesis. Recent insights have led to the development of novel pharmacotherapies with the potential to significantly impact each disease. This review will summarize the preclinical and clinical data for these emerging treatments for AL and ATTR amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.